Study S000882

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

ClinicalTrials.gov record

Registration

Registration: NCT06952530
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 487
Start: 2025-04-30
Primary completion: 2027-09
Lead sponsor: Eli Lilly and Company
Conditions: Hypertension
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZL2; OTHER:J2A-MC-GZPL

Registered primary outcomes

Change from Baseline in office Systolic Blood Pressure (SBP) [Baseline to Week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.